HTG Molecular Diagnostics, Inc.
HTG Molecular Diagnostics, Inc.
Your view on HTGMQ
Overview
What the company does, where it operates, and who runs it.
About HTG Molecular Diagnostics, Inc.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- John L. Lubniewski
- Headquarters
- 3430 East Global Loop, Tucson, AZ, US
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- John L. Lubniewski
- Headquarters
- 3430 East Global Loop, Tucson, AZ, US
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets.
Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq Oncology Biomarker Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel.
The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories.
The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
On June 5, 2023, HTG Molecular Diagnostics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for HTG Molecular Diagnostics, Inc. from FRC's valuation model, read against the market price. HTGMQ last traded at $0.0001; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for HTG Molecular Diagnostics, Inc.. Starting points for HTG Molecular Diagnostics, Inc.: EPS -$24.28, beta 2.76 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for HTG Molecular Diagnostics, Inc.. HTG Molecular Diagnostics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for HTG Molecular Diagnostics, Inc.. Trailing twelve-month EPS for HTG Molecular Diagnostics, Inc. stands at -$24.28. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Analyst Ratings
- Strong Buy0
- Buy1
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrJun 2024 | Next QtrSep 2024 | Current YearFY Dec 2023 | Next YearFY Dec 2024 |
|---|---|---|---|---|
| Avg. estimate | -$2.16 | -$2.16 | -$4.63 | -$1.06 |
| Low estimate | -$2.16 | -$2.16 | -$4.63 | -$1.06 |
| High estimate | -$2.16 | -$2.16 | -$4.63 | -$1.06 |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago EPS | — | — | -$24.28 | — |
| Growth | — | — | +80.9% | — |
Revenue Estimate
| Revenue | Current QtrJun 2024 | Next QtrSep 2024 | Current YearFY Dec 2023 | Next YearFY Dec 2024 |
|---|---|---|---|---|
| Avg. estimate | $5.30M | $5.80M | $6.40M | $15.00M |
| Low estimate | $5.30M | $5.80M | $6.40M | $15.00M |
| High estimate | $5.30M | $5.80M | $6.40M | $15.00M |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago revenue | — | — | $6.37M | — |
| Growth | — | — | +0.5% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for HTG Molecular Diagnostics, Inc.. HTG Molecular Diagnostics, Inc. has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- BIOCQBiocept, Inc.Medical - Diagnostics & Research$263
- BRSFBrain Scientific Inc.Medical - Devices$124
- BSPMBiostar Pharmaceuticals, Inc.Drug Manufacturers - Specialty & Generic$264
- CLVRClever Leaves Holdings Inc.Drug Manufacturers - Specialty & Generic$702
- CRFTFBC Craft Supply Co. Ltd.Drug Manufacturers - Specialty & Generic$23
- HLTHQCue Health Inc.Medical - Specialties$159
- MDVLQMedAvail Holdings, Inc.Medical - Pharmaceuticals$161
- NEXINexImmune, Inc.Medical - Pharmaceuticals$279
More Medical - Diagnostics & Research companies
- SHL.AXSonic Healthcare LimitedASX
- SKHCFSonic Healthcare LimitedOTC$7.9B
- AAgilent Technologies, Inc.NYSE$48.8B
- ABDXFAbingdon Health PlcOTC$13M
- ACL.AXAustralian Clinical Labs LimitedASX
- ADVBAdvanced Biomed Inc. Common StockNASDAQ$4M
- ANPCFCellbxhealth PLCOTC$4M
- ARYCArrayit CorporationOTC$79,348
- AVCR.VAvricore Health Inc.TSXV$3M
- AVCRFAvricore Health Inc.OTC$6M
- BDSXBiodesix, Inc.NASDAQ$73M
- BDX.AXBCAL Diagnostics LimitedASX
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for HTG Molecular Diagnostics, Inc.. Coverage tracks HTG Molecular Diagnostics, Inc. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of HTG Molecular Diagnostics, Inc.